Cargando…
A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee
In the current study, sixty healthy older adults aged 50 years or older, and who were light to moderate coffee drinkers, were administered 6g of a decaffeinated green coffee blend (NESCAFÉ Green Blend coffee; GB) or 540mg pure chlorogenic acids (CGA) or placebo in a double-blind acute cross-over des...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857311/ https://www.ncbi.nlm.nih.gov/pubmed/24349389 http://dx.doi.org/10.1371/journal.pone.0082897 |
_version_ | 1782295148916375552 |
---|---|
author | Camfield, David A. Silber, Beata Y. Scholey, Andrew B. Nolidin, Karen Goh, Antionette Stough, Con |
author_facet | Camfield, David A. Silber, Beata Y. Scholey, Andrew B. Nolidin, Karen Goh, Antionette Stough, Con |
author_sort | Camfield, David A. |
collection | PubMed |
description | In the current study, sixty healthy older adults aged 50 years or older, and who were light to moderate coffee drinkers, were administered 6g of a decaffeinated green coffee blend (NESCAFÉ Green Blend coffee; GB) or 540mg pure chlorogenic acids (CGA) or placebo in a double-blind acute cross-over design, with cognitive and mood assessments pre-dose, 40-mins and 120-mins post-dose. The primary outcome measure was accuracy in Rapid Visual Information Processing (RVIP). Secondary cognitive outcome measures included RVIP reaction time as well as Inspection time (IT), Jensen Box decision/reaction times, serial subtraction and N-Back working memory. Secondary mood measures included Bond-Lader and caffeine Research visual analogue scales (VAS). No significant treatment effects were found for the primary outcome measure, although significant effects were found amongst secondary measures. Overall, CGA in isolation was not found to significantly improve cognitive function relative to placebo whereas the GB was found to improve sustained attention as measured by the N-Back task in comparison to placebo overall (t=2.45,p=.05), as well as decision time on a 2-choice reaction time task (Jensen box) in comparison to placebo at 40 minutes post-dose (t=2.45,p=.05). Similarly, GB was found to improve alertness on both the Bond-Lader at 120 minutes relative to CGA (t=2.86, p=0.02) and the caffeine Research VAS relative to CGA (t=3.09, p=0.009) and placebo (t=2.75,p=0.02) at 120 minutes post-dose. Both the GB and CGA were also found to significantly improve symptoms of headache at 120 minutes relative to placebo (t=2.51,p=0.03 and t=2.43,p=.04 respectively), whilst there was a trend towards a reduction in jitteriness with GB and CGA in comparison to placebo at 40 minutes post-dose (t=2.24,p=0.06 and t=2.20,p=0.06 respectively). These findings suggest that the improvements in mood observed with GB, but not the improvements in cognitive function, are likely to some extent to be attributable to CGAs. Trial Registration: Australia New Zealand Clinical Trials Registry ACTRN12611000067976 www.anzctr.org.au |
format | Online Article Text |
id | pubmed-3857311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38573112013-12-13 A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee Camfield, David A. Silber, Beata Y. Scholey, Andrew B. Nolidin, Karen Goh, Antionette Stough, Con PLoS One Research Article In the current study, sixty healthy older adults aged 50 years or older, and who were light to moderate coffee drinkers, were administered 6g of a decaffeinated green coffee blend (NESCAFÉ Green Blend coffee; GB) or 540mg pure chlorogenic acids (CGA) or placebo in a double-blind acute cross-over design, with cognitive and mood assessments pre-dose, 40-mins and 120-mins post-dose. The primary outcome measure was accuracy in Rapid Visual Information Processing (RVIP). Secondary cognitive outcome measures included RVIP reaction time as well as Inspection time (IT), Jensen Box decision/reaction times, serial subtraction and N-Back working memory. Secondary mood measures included Bond-Lader and caffeine Research visual analogue scales (VAS). No significant treatment effects were found for the primary outcome measure, although significant effects were found amongst secondary measures. Overall, CGA in isolation was not found to significantly improve cognitive function relative to placebo whereas the GB was found to improve sustained attention as measured by the N-Back task in comparison to placebo overall (t=2.45,p=.05), as well as decision time on a 2-choice reaction time task (Jensen box) in comparison to placebo at 40 minutes post-dose (t=2.45,p=.05). Similarly, GB was found to improve alertness on both the Bond-Lader at 120 minutes relative to CGA (t=2.86, p=0.02) and the caffeine Research VAS relative to CGA (t=3.09, p=0.009) and placebo (t=2.75,p=0.02) at 120 minutes post-dose. Both the GB and CGA were also found to significantly improve symptoms of headache at 120 minutes relative to placebo (t=2.51,p=0.03 and t=2.43,p=.04 respectively), whilst there was a trend towards a reduction in jitteriness with GB and CGA in comparison to placebo at 40 minutes post-dose (t=2.24,p=0.06 and t=2.20,p=0.06 respectively). These findings suggest that the improvements in mood observed with GB, but not the improvements in cognitive function, are likely to some extent to be attributable to CGAs. Trial Registration: Australia New Zealand Clinical Trials Registry ACTRN12611000067976 www.anzctr.org.au Public Library of Science 2013-12-09 /pmc/articles/PMC3857311/ /pubmed/24349389 http://dx.doi.org/10.1371/journal.pone.0082897 Text en © 2013 Camfield et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Camfield, David A. Silber, Beata Y. Scholey, Andrew B. Nolidin, Karen Goh, Antionette Stough, Con A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee |
title | A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee |
title_full | A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee |
title_fullStr | A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee |
title_full_unstemmed | A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee |
title_short | A Randomised Placebo-Controlled Trial to Differentiate the Acute Cognitive and Mood Effects of Chlorogenic Acid from Decaffeinated Coffee |
title_sort | randomised placebo-controlled trial to differentiate the acute cognitive and mood effects of chlorogenic acid from decaffeinated coffee |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857311/ https://www.ncbi.nlm.nih.gov/pubmed/24349389 http://dx.doi.org/10.1371/journal.pone.0082897 |
work_keys_str_mv | AT camfielddavida arandomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee AT silberbeatay arandomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee AT scholeyandrewb arandomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee AT nolidinkaren arandomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee AT gohantionette arandomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee AT stoughcon arandomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee AT camfielddavida randomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee AT silberbeatay randomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee AT scholeyandrewb randomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee AT nolidinkaren randomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee AT gohantionette randomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee AT stoughcon randomisedplacebocontrolledtrialtodifferentiatetheacutecognitiveandmoodeffectsofchlorogenicacidfromdecaffeinatedcoffee |